Under the Hood: Understanding the Features of Mucin in Pseudomyxoma Peritonei

Villarejo-Campos, Pedro; García-Arranz, Mariano; Qian, Siyuan; Galanes, Santos Jiménez de los; Domínguez-Prieto, Víctor; Pinto, Felipe Velez; Castellano, Ismael Guijo; Jiménez-Fuertes, Montiel; Guadalajara, Héctor; García-Olmo, Damián

doi:10.3390/jcm12124007

Cited by 2 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the interaction relationship and mechanism between these bacteria and MUC2 have not been reported. Villarejo-Campos et al [86] performed 16S sequencing on PMP mucinous tumor tissue, and the results suggested that Proteobacteria was the dominant phylum and Pseudomonas was the dominant genus. Previous studies have shown that Pseudomonas is directly related to the overexpression of mucins [87].…”

Section: Intestinal Floramentioning

confidence: 99%

See 1 more Smart Citation

Progress in Biological Research and Treatment of Pseudomyxoma Peritonei

Li,

Liu,

2024

Cancers

View full text Add to dashboard Cite

Pseudomyxoma peritonei (PMP) is a rare disease characterized by extensive peritoneal implantation and mass secretion of mucus after primary mucinous tumors of the appendix or other organ ruptures. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is currently the preferred treatment, with excellent efficacy and safety, and is associated with breakthrough progress in long-term disease control and prolonged survival. However, the high recurrence rate of PMP is the key challenge in its treatment, which limits the clinical application of multiple rounds of CRS-HIPEC and does not benefit from conventional systemic chemotherapy. Therefore, the development of alternative therapies for patients with refractory or relapsing PMP is critical. The literature related to PMP research progress and treatment was searched in the Web of Science, PubMed, and Google Scholar databases, and a literature review was conducted. The overview of the biological research, treatment status, potential therapeutic strategies, current research limitations, and future directions associated with PMP are presented, focuses on CRS-HIPEC therapy and alternative or combination therapy strategies, and emphasizes the clinical transformation prospects of potential therapeutic strategies such as mucolytic agents and targeted therapy. It provides a theoretical reference for the treatment of PMP and the main directions for future research.

show abstract

Section: Intestinal Floramentioning

confidence: 99%

“…or whether it was the colonization of Pseudomonas [86] or other reasons, the mechanism of this kind of tumor cell-independent mucin production merits further discussion.…”

Section: Future Directions and Conclusionmentioning

confidence: 99%

Progress in Biological Research and Treatment of Pseudomyxoma Peritonei

Li,

Liu,

2024

Cancers

View full text Add to dashboard Cite

show abstract

“…It is associated with malignant tumors in the appendix (see Figures 4 and 5); however, there is a debate ove the specific epithelium from which it arises. The hypothesis that ovaries might be an al ternative main location of PMP genesis is regarded as plausible, but lacks a complete ex planation in terms of immunochemistry [3] (see Figures 6 and 7). In a study designed by Yan [4], the tumors exhibited positivity for CK20, CDX2, CEA, and Villin.…”

Section: Introductionmentioning

confidence: 99%

Ovarian Causes of Pseudomyxoma Peritonei (PMP)—A Literature Review

Ionescu,

Marincas,

Madge

et al. 2024

Cancers

View full text Add to dashboard Cite

Background. Pseudomyxoma peritonei (PMP) is a rare, progressive, slowly growing, inadequately understood neoplasm with a 5-year progression-free survival rate of as low as 48%. It is characterized by varying degrees of malignancy and the production of mucinous and gelatinous structures. Typically, the development of pseudomyxoma peritonei is associated with the rupture of appendiceal mucinous tumors and other gastrointestinal or ovarian mucinous tumors. The goal of our literature review was to identify various aspects that characterize the ovarian causes of pseudomyxoma peritonei. Materials and methods. The authors performed an extensive literature search between 1 February 2024 and 2 March 2024 on the following databases: Pubmed, Scopus, Oxford Journals, and Reaxys, and the findings were summarized into seven main clinical and paraclinical situations. Results. According to our research, the main instances in which pseudomyxoma peritonei can be triggered by an ovarian cause are the following: (1) mucinous cystadenoma; (2) mucinous ovarian cancer; (3) colon cancer with ovarian metastasis; (4) malignant transformation of an ovarian primary mature cystic teratoma; (5) appendiceal mucocele with peritoneal dissemination mimicking an ovarian tumor with peritoneal carcinomatosis; (6) mucinous borderline tumor developing inside an ovarian teratoma; and (7) the association between a mucinous bilateral ovarian cancer and a colonic tumor. Conclusions. In our study, we aimed to provide a comprehensive overview of the ovarian causes of pseudomyxoma peritonei, including its epidemiology, imagery characteristics, symptoms, current treatment, and promising future therapies, in the hopes of finding feasible solutions, as a lack of understanding of this mucus-secreting malignant disease increases the risk of delayed diagnosis or uncontrolled deterioration.

show abstract

Under the Hood: Understanding the Features of Mucin in Pseudomyxoma Peritonei

Cited by 2 publications

References 34 publications

Progress in Biological Research and Treatment of Pseudomyxoma Peritonei

Progress in Biological Research and Treatment of Pseudomyxoma Peritonei

Ovarian Causes of Pseudomyxoma Peritonei (PMP)—A Literature Review

Contact Info

Product

Resources

About